212 related articles for article (PubMed ID: 24988441)
1. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
Lees JS; Dobbin SJH; Elyan BMP; Gilmour DF; Tomlinson LP; Lang NN; Mark PB
Nephrol Dial Transplant; 2023 Jun; 38(7):1666-1681. PubMed ID: 36318455
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
4. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
7. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.
Neves KB; Rios FJ; Jones R; Evans TRJ; Montezano AC; Touyz RM
Cardiovasc Res; 2019 Apr; 115(5):978-988. PubMed ID: 30753341
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
[TBL] [Abstract][Full Text] [Related]
9. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Zhu X; Wu S; Dahut WL; Parikh CR
Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
[TBL] [Abstract][Full Text] [Related]
10. Vascular toxicity associated with anti-angiogenic drugs.
Neves KB; Montezano AC; Lang NN; Touyz RM
Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
[TBL] [Abstract][Full Text] [Related]
11. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
[TBL] [Abstract][Full Text] [Related]
12. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
13. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
Abdel-Qadir H; Ethier JL; Lee DS; Thavendiranathan P; Amir E
Cancer Treat Rev; 2017 Feb; 53():120-127. PubMed ID: 28104567
[TBL] [Abstract][Full Text] [Related]
15. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.
Kovalenko I; Lynn Ng W; Geng Y; Wang Y; Msaouel P; Bhatia S; Grivas P; Benkhadra R; Alhalabi O
Front Oncol; 2023; 13():1238517. PubMed ID: 38239644
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
17. Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension.
van Doorn L; Visser WJ; van Dorst DCH; Mirabito Colafella KM; Koolen SLW; de Mik AVE; Garrelds IM; Bovée DM; de Hoop EO; Bins S; Eskens FALM; Hoorn EJ; Jan Danser AH; Mathijssen RHJ; Versmissen J
Br J Cancer; 2023 Jan; 128(2):354-362. PubMed ID: 36357702
[TBL] [Abstract][Full Text] [Related]
18. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
19. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
Horsley L; Marti K; Jayson GC
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]